RT Book, Section A1 Hilal-Dandan, Randa A1 Brunton, Laurence L. SR Print(0) ID 1127554988 T1 Targeted Therapies: Tyrosine Kinase Inhibitors, Monoclonal Antibodies, and Cytokines T2 Goodman and Gilman's Manual of Pharmacology and Therapeutics, 2e YR 2016 FD 2016 PB McGraw-Hill Education PP New York, NY SN 9780071769174 LK accessbiomedicalscience.mhmedical.com/content.aspx?aid=1127554988 RD 2024/03/28 AB Many new agents are available to block the fundamental mutations that cause specific cancers: aberrant growth factor receptors, dysregulated intracellular signaling pathways, defective DNA repair and apoptosis, and tumor angiogenesis. The primary tools for inhibiting these targets are monoclonal antibodies that attack cell surface receptors and antigens, and synthetic small molecules that enter cells and engage critical enzymes. These 2 classes of drugs have very different pharmacological properties.